During the screening process, we recorded age, height, weight, and body mass index. We collected self-reported demographics (e.g., ethnicity and race), medical history including duration and type of cancer, history of falls in the past year, comorbidities, cancer diagnosis, self-report number of prescription medicines and over-the-counter medicines taken per day.

Health-related quality of life was assessed using the Functional Assessment of Cancer Therapy–General (FACT-G) survey [24]. Self-reported pain level was extracted from FACT-G. Plantar numbness severity was evaluated by the vibration perception threshold (VPT) as per prior studies and using established thresholds; a VPT value ≥ 25 volts was classified as severe plantar numbness [2527]. The Center for Epidemiologic Studies Depression scale (CES-D) short-version scale was used to identify patients with depression based on a cut-off score ≥ 16 [28]. The Montreal Cognitive Assessment (MoCA) was used to identify subjects with cognitive impairment based on a cut-off score ≤ 25 [29]. The Fall Efficacy Scale-International (FES-I) questionnaire to determine concern for falls; participants were classified as having high concern for falling if FES-I ≥ 23 based on previous studies [3032]. All questionnaires were administered by the assessor.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.